Autologous gamma delta T cell therapy (TC BioPharm)(Autologous gamma delta T cell therapy (TC BioPharm))

概要

基本信息

药物类型

T细胞疗法

别名

Autologous T Lymphocytes、Autologous d T Lymphocytes、Autologous g T Lymphocytes

+ [1]

靶点-

作用机制

免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤呼吸系统疾病皮肤和肌肉骨骼疾病+ [2]

在研适应症-

非在研适应症

肾肿瘤肝癌黑色素瘤+ [1]

原研机构

TC Biopharm Ltd.

在研机构-

非在研机构

TC Biopharm Ltd.M Group Holdings Ltd.

最高研发阶段终止临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的临床试验

NCT03790072 / Completed临床1期

Safety and Efficacy of Ex-vivo Expanded Allogeneic γδ T-lymphocytes (OmnImmune®) in Patients With Active Relapsed or Refractory Acute Myeloid Leukaemia (AML) Who Are Not Eligible for or do Not Consent to High Dose Salvage Chemotherapy and/or Allogeneic Haematopoietic Cell Transplantation (HCT). A Dose Escalation, Open-label, Phase I Study

This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.

开始日期2018-11-27

申办/合作机构

TC Biopharm Ltd.

NCT02459067 / Terminated临床2期

Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.

开始日期2015-12-01

申办/合作机构

TC Biopharm Ltd.

JPRN-UMIN000006128 / Completed临床2期IIT

Adoptive immunotherapy using zoledronate-expanded autologous gamma/delta T cells for patients with non-small cell lung cancer refractory to standard treatment. - Zoledronate-expanded autologous gamma/delta T cell therapy for NSCLC

开始日期2012-07-01

申办/合作机构

The University of Tokyo Hospital

100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的临床结果

登录后查看更多信息

100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的转化医学

登录后查看更多信息

100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的专利（医药）

登录后查看更多信息

3

项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的文献（医药）

2024-10-25·Organic Letters

Cinchona Organocatalyzed Enantioselective Amination for Quaternized Serines as Tertiary Amides

Article

作者: Spicer, Christopher D. ; Hunter, Roger ; Bhana, Ashlyn D. ; Su, Hong ; Venter, Gerhard A. ; Petersen, Wade F. ; Masithi, Phathutshedzo

Herein, we describe a Cinchona-aminocatalyzed enantioselective α-hydrazination of an α-formyl amide for the production of protected quaternized serines as tertiary amides with ee's of generally >98% and ≤99% yields. The proposed TS model supported by density functional theory calculations involves a quinuclidinium ion Brønsted acid-assisted delivery of D^tBAD, which occurs from the Re face of an H-bonded enaminone when using a 9S-cinchonamine catalyst, resulting in a hydrazide with the R-configuration as determined by X-ray analysis.

2011-09-01·British Journal of Cancer1区 · 医学

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

1区 · 医学

Article

作者: S R Mattarollo ; T Hagi ; H Tokuyama ; K Suzuki ; K Yokokawa ; M Nieda ; A J Nicol

BACKGROUNDAdoptive transfer of ex vivo expanded autologous Vγ9Vδ2 T cells may be of therapeutic benefit for cancer because of their potent direct cytotoxicity towards tumour cells, synergistic cytotoxicity when combined with aminobisphosphonates and enhancement of antibody-dependent cell-mediated cytotoxicity.METHODSTo determine the feasibility and clinical safety of therapy with ex vivo expanded, activated Vγ9Vδ2 T cells in combination with zoledronate, we enrolled 18 subjects with advanced solid tumours into a phase I clinical study. Administered indium(111)-oxine-labelled Vγ9Vδ2 T cells were tracked in a cohort of patients.RESULTSAdministered Vγ9Vδ2 T cells had an activated effector memory phenotype, expressed chemokine receptors predictive of homing to peripheral tissues and were cytotoxic in vitro against tumour targets. Adoptively transferred Vγ9Vδ2 T cells trafficked predominantly to the lungs, liver and spleen and, in some patients, to metastatic tumour sites outside these organs. No dose-limiting toxicity was observed, but most patients progressed on study therapy. However, three patients administered Vγ9Vδ2 T cells while continuing previously ineffective therapy had disease responses, suggesting an additive effect.CONCLUSIONTherapy with aminobisphosphonate-activated Vγ9Vδ2 T cells is feasible and well tolerated, but therapeutic benefits appear only likely when used in combination with other therapies.

2007-03-01·The Journal of Physical Chemistry A3区 · 化学

Geometric Structure of X(AuPH₃)₄⁺ (X = N, P, As, Sb): T_d or C₄_v?

3区 · 化学

Article

作者: Fang, Hua ; Wang, Shu-Guang

The geometric structures of X(AuPH3)4+ (X = N, P, As, Sb) compounds have been determined by DFT and ab-initio methods. In agreement with experiment, N(AuPH3)4+ is Td and As(AuPH3)4+ is C4v with an apical As atom. Calculated molecular and experimental crystal structure parameters are compared. The structures of X(AuPH3)4+ (X = P, Sb) are predicted. P(AuPH3)4+ favors Td, as confirmed by CC2. The closed-shell interaction distances of Au...Au from Xalpha are consistent with the experimental values. The electronic structures and chemical deformation densities are analyzed.

100 项与 Autologous gamma delta T cell therapy (TC BioPharm) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾肿瘤	临床3期	英国	TC Biopharm Ltd.	-
肝癌	临床3期	日本	M Group Holdings Ltd.	-
黑色素瘤	临床3期	英国	TC Biopharm Ltd.	-
非小细胞肺癌	临床3期	英国	TC Biopharm Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2011	N/A	早期乳腺癌辅助	74	TC therapy	夢淵夢餘觸鏇餘網網蓋(簾蓋鹽願憲夢繭膚鏇範) = 窪衊壓膚窪廠鏇窪襯築鹽膚鬱襯鹽醖鑰遞範鹹 (積廠獵遞衊窪製簾繭壓 )	-	2011-05-20
				docetaxel (No prophylaxis)	夢淵夢餘觸鏇餘網網蓋(簾蓋鹽願憲夢繭膚鏇範) = 蓋獵餘餘範鏇壓襯獵網鹽膚鬱襯鹽醖鑰遞範鹹 (積廠獵遞衊窪製簾繭壓 )
Tandem Meetings ASTCT and CIBMTR2009	N/A	淋巴瘤	-	Autologous Cytotoxic T Lymphocytes (LMP2 CTLs)	夢製壓積齋鑰網鹽鏇觸(獵艱鏇顧衊襯蓋壓製壓) = 蓋網範壓獵蓋窪憲繭鹽鏇製鑰範遞壓簾醖艱夢 (觸鬱鑰繭廠鬱製獵築壓 ) 更多	-	2009-02-01
				Autologous Cytotoxic T Lymphocytes (LMP1/2 CTLs)	夢構襯鹽廠餘淵廠醖築(淵壓襯艱觸衊網齋顧繭) = 艱鹽鏇鹽窪蓋襯簾製鑰鹹醖淵築觸顧願鹹遞網 (夢鏇襯繭顧齋願糧夢製 )